Group 10Created with Sketch.
Group 11Created with Sketch.
52 Week High-Low
Page 1Created with Sketch.
Net Yield
Group 12Created with Sketch.
Hist / Pros Per
Page 1Created with Sketch.
Equity Market Cap

ONT develop and supply instruments which can be used to read the genetic code of an organism. This information can help to find treatments to diseases. The sequencing market is not without competition however; in Illumina ONT finds a formidable opponent.

However, whilst Illumina remain the largest player in the market, PacBio present the most direct competition to ONT as the sequencing market is bifurcated into short-read technology (used by Illumina) and long-read (operated by PacBio and ONT). Short-read technology is more established than long-read and will likely remain the dominant sequencing solution for years to come.

However, there is a 9% or so ‘dark zone’ of the human genome which can’t be sequenced by short-read techniques and this is where ONT hopes to make traction.

ONT’s long-read technology is only just emerging from its proof-of-concept phase and its instruments are currently involved in a series of trials that will be crucial to catalyse further adoption. Whilst promising, ONT still have a lot to prove.

Managing your wealth

Managing your wealth

Understanding Finance

Helping clients understand what we do is key to building relationships. To explain some of the industry jargon that creeps into our world, we’ve pulled together a section of our site to help.

Also in this issue